Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS

Journal of Infectious Diseases

Volumn 163, Issue 6, 1991, Pages 1348-1351

  Jacobson, Mark A ^a   Drew, W Lawrence ^b   Feinberg, Judith ^b   O'Donnell, James J ^b   Whitmore, Paul V ^b   Miner, Richard D ^b   Parenti, David ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; COMPLICATION; CYTOMEGALOVIRUS INFECTION; DRUG RESISTANCE; DRUG THERAPY; HUMAN; HUMAN CYTOMEGALOVIRUS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RETINITIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIVIRAL AGENTS; CASE REPORT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MICROBIAL; EYE INFECTIONS, VIRAL; FOSCARNET; GANCICLOVIR; HUMAN; MALE; OPHTHALMOSCOPY; PHOSPHONOACETIC ACID; RETINITIS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026006264     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/163.6.1348     Document Type: Article

References (15)

1. Abramowicz M, ed. Ganciclovir. Med Lett Drugs Ther 1989;31:79-80.
2. Jacobson MA, O'Donnell JJ, Porteous D, Brodie HR, Mills J. Natural history of ganciclovir-treated cytomegalovirus retinitis and gastrointestinal disease. Q J Med 1988;67:473-86.
3. Felsenstein D, d'Amico DJ, Hirsch MS, et al. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med 1985;103:377-80.
4. Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985;103:368-73.
5. Mar EC, Cheng YC, Huang ES. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1983;24:518-21.
6. Tyms AS, Davis JM, Jeffries DJ, Meyers JD. BW759U, an analogue of acyclovir, inhibits human cytomegalovirus in vitro. Lancet 1984;2: 924-5.
7. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985;152:833-4.
8. Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-61.
9. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
10. Biron KK, Stanat SC, Reardon J, Erice A, Balfour H, Jordan MC. Ganciclovir-resistant clinical isolates of CMV: antiviral susceptibility profiles and mode of resistance studies [abstract 65]. In: Program and abstracts of II International Cytomegalovirus Workshop, San Diego, 1989.
11. Oberg B. Antiviral effects of phosphonoformate. Pharmacotherapy 1983;19:387-415.
12. Jacobson MA, Causey D, Hardy D, et al. Tolerance and efficacy of daily intravenous maintenance foscarnet therapy for cytomegalovirus retinitis [abstract M.B.P.123]. In: Program and abstracts: V International Conference on AIDS (Montreal). Ottawa: International Development Research Centre, 1989.
13. Katlama C, Dohin E, Massin-Cochereau I, Fassin D, Le Hoang P, Gentilini M. Prophylaxis of CMV retinitis relapse: evaluation of foscarnet in maintenance therapy [abstract M.B.P.117]. In: Program and abstracts: V International Conference on AIDS (Montreal). Ottawa: International Development Research Centre, 1989.
14. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1990;163:716-9.
15. Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293-6.